🇺🇸 FDA
Patent

US 11053262

Heterocyclic amide compounds having RORyT inhibitory action

granted A61PA61P1/04A61P17/06

Quick answer

US patent 11053262 (Heterocyclic amide compounds having RORyT inhibitory action) held by Takeda Pharmaceutical Company Limited expires Mon Jul 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Jul 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61P, A61P1/04, A61P17/06, A61P19/02, A61P25/00